Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
cuz I'm your favorite . . .
DCTH just keeps on coming
CRKT, nibble nibble
MKRS, bottom?
weeeeeee!
Hoping against hope.
Morning all. (Is it Friday yet?)
PHPG, could be finding new highs soon.
NSEO
DCTH, just keeps rolling along . . .
The horror, the horror . . .
PFCE bravely seeking new bottoms daily.
Hi all . . .
Yeah, right, Frankie; they don't bite, much.
PHPG . . . thanks
PHPG
Posts record results
http://biz.yahoo.com/prnews/050124/nym156_1.html
Morning all . . .
EMFP does have umph but not necessarily because it is one of Gary Grobbel's picks. It is one of his picks because it has umph. It has recently received approval as an approved vendor to the US military, and it is being distributed in Asia by Itochu. I wish it were so easy that anything GPG write up goes up but he can't move a stock by himself. This is going to be one of his winners, I believe, because the company is going to come through, and unfortunately there is going to be a big need for their products.
And HAPPY BIRTHDAY TO CANDICE!!!!!
Candice mentioned CTTG repeatedly over the last week. That's the only reason it was on my watch screen.
It takes me all week to really get going.
CTTG carpe diem
And I was swooning. POCI may be turning around again.
I only called Mankey 'he' in respect to her preference to do the female-to-male thing sometimes (and she pulls it of quite well, thank-you). I would rather think of her as NOW rather than TODAY as TODAY rather sucks. Wish I'd bought INSA. When Mankey whispered it in my ear, I was only aware of her hot breath.
It looks like his pants are plasticene, but on closer inspection, he doesn't seem to have any legs. If this is the case, he could not be jumping and must, in fact, be getting pulled up and down by strings. I do not wish to think of the possible implications, like exactly who is the puppetmaster here? The shirt, based on the collar, seems to be a pullover, probably a promo shirt for a beer company. Milwaukee's Best? Further inspection reveals he needs both a comb and a dentist. I wish I hadn't looked, but will continue to have faith in his wisdom.
DCTH. Woohoo.
Good morning, and don't forget, we like ksuave on Fridays.
Disappointing. But there's always tomorrow, and lots of stocks out there.
TALL is largely otcbargain's baby on Bobwin's thread. He's not my best friend.
One flew right over my head a few days ago!
TALL?
PFCE -- I like it.
When SEHO hits the newswires, it's going to go boffo, maybe.
Reason for SEHO surge. Could be more here.
http://www.businessweek.com/technology/content/jan2005/tc20050120_5906_tc024.htm
SEHO
I like the idea of just putting attractive charts up there, and that's a good niche for this board, but the notion of expressing opinions is not really all that problematic between experienced traders. What happens if the rec falls on its arse? Nothing. Nobody is liable. I trade tips with different people (whom I trust) all the time, and if one tanks, its not the fault or responsibility of the person who made the tip. Period. One buys and dies alone. That's jmo.
Is it inappropriate to ask if there are any burning buy-right-nows out there?
Oh, and, good mornin'.
DCTH
National Cancer Institute to Present Treatment Results With Delcath System at Multidisciplinary Cancer Meeting
Thursday January 20, 7:59 am ET
STAMFORD, Conn., Jan. 20 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH - News) was informed by H. Richard Alexander, MD, head of the NCI's Surgical Metabolism Section, that his colleague, Jeffrey Farma, MD, will present the preliminary results from treating 15 melanoma patients with the Delcath system to the 2005 Gastrointestinal Cancers Symposium in Hollywood, Florida January 27-29.
The three-day, multidisciplinary symposium on gastrointestinal cancers is co-sponsored by the American Society of Clinical Oncology, the American Gastroenterological Association, the American Society for Therapeutic Radiology and Oncology, and the Society of Surgical Oncology. This is the second consecutive year the meeting will be held and also marks the second year a presentation will be given on the use of the Delcath system.
The research team at the NCI which conducted the Phase I study being reported on at the meeting has since started Phase II clinical studies to provide further data to support the safety and efficacy claims that will form the basis of eventual applications for approval to the FDA.
The Delcath system delivers high-dose chemotherapy directly to the liver via the hepatic artery. As blood exits the liver, special Delcath filters trap the chemotherapy, protecting the rest of the body from excessive toxicity. The procedure is repeatable and less invasive than traditional ways of performing isolated perfusion to effect dose-directed therapy of specific body organs or regions.
"We're experiencing growing interest within the medical community to learn more about our cancer treatment," Delcath CEO M.S. Koly said. "Although we have completed several phases of clinical studies with multiple drugs to demonstrate the usefulness of the system, it is also critical that physicians throughout the country become knowledgeable about its benefits. The upcoming meeting is an important mechanism for doctors to discuss the Delcath system critically with their peers, and we are pleased the NCI Investigators continue to be invited to share their knowledge in this area."
Delcath is a developer of isolated perfusion technology for organ or region-specific delivery of therapeutic agents. Six U.S., and three foreign issued patents cover its technology. The company is headquartered in Stamford, CT.
This release contains "forward-looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. Delcath plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, its ability to consummate, and the timing of, acquisitions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond its control. Therefore, there can be no assurance than any forward-looking statement will prove to be accurate.
Contact:
M.S. Koly Thomas Redington
Chief Executive Officer Redington, Inc.
Delcath Systems, Inc. 203/222-7399
203/323-8668 212/926-1733
http://www.delcath.com http://www.redingtoninc.com
CLTK flying after hours, earnings out
CLTK moving (pre-earnings)
You might want to look at EMFP as a bird flu play. Thanks.